A $499 body scan as a recruitment funnel for brain implants

The useful question about a pre-screen is not what it can find. It is what it can discard, and at whose expense.

Neuralink's PRIME Study runs on narrow eligibility: quadriplegia from spinal cord injury or ALS ^[6]. A one-hour session reading skin health, cardiovascular function and assorted biological metrics ^[2] cannot establish either. Crypto Briefing's own account concedes the point, noting that confirming a spinal cord injury diagnosis or staging ALS normally requires specialised neurological evaluation ^[8]. So the plausible job is subtraction: flag a disqualifying cardiovascular or systemic problem and drop that candidate before targeted neurological screening starts ^[9], ideally before anyone books time in a neurosurgery clinic ^[13]. Given that implanting a device in the wrong patient carries severe consequences ^[12], a cheap early filter has obvious value to the sponsor.

It has less obvious value to the person scanned, who paid $499 for a preventive-health snapshot about themselves ^[3]. The reported arrangement uses consented data, meaning users would have to opt in to their information being run for Neuralink screening, and the mechanics of that opt-in are not described ^[7]. That gap is the whole story. The question a regulator eventually asks is not whether a box was ticked, it is whether a yes given in a preventive-health context covers being sorted, by a third party, for enrolment in a surgical device trial.

The calendar makes the consent problem sharper rather than hypothetical. As of 23 August 2026 no formal partnership had been confirmed through conventional channels; the collaboration surfaced on social media ^[10]. Neko's first American clinic is scheduled to open in New York City on 24 September 2026 ^[5], 32 days after that ^[11]. The $700m Series C that closed on 15 July 2026 was raised to fund exactly this US push ^[4]. A screening pipeline was therefore described in public before the clinic that would feed it had seen a single American customer, which means the consent language governing those scans is presumably still being drafted. That language is the asset, not the sensors.

For anyone else sitting on a preventive-health dataset, the mechanism generalises with unpleasant ease. Millions of data points per patient ^[2] is a number that sells a consumer product on thoroughness, and thoroughness is precisely what makes a dataset attractive to somebody with a recruitment bottleneck. Trial sponsors pay for screening today. A filter assembled from records that consumers already funded is cheaper than one built from scratch, and the cost saving accrues entirely on the sponsor's side of the ledger.

Neither company has confirmed any of this through normal channels ^[10]. Treat the arrangement as reported, not established. Treat the secondary-use question as established regardless, because the moment a health dataset can shorten someone else's recruitment funnel, its owner has a second business it may not have documented.